about
Structural integrity versus radiographic progression in rheumatoid arthritisEffects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trialsTreatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.Novel mechanisms of action of the biologicals in rheumatic diseases.Ultrasonography in the diagnosis and management of patients with inflammatory arthritides.Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphosBiomarkers in psoriatic arthritis: a systematic literature review.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to dateThe role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry.Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designsIncidence of cancer in patients with spondyloarthritis treated with anti-tnf drugs.Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting.Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives.Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores.Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.Predicting response to anti-TNF treatment in rheumatoid arthritis patients.Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis.The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockadeSarilumab: patient-reported outcomes in rheumatoid arthritisNewly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol MetabolismTocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
P50
Q26777897-59EF192D-9737-42CE-8B6A-0445B04AB250Q30841797-E0B33C95-6049-4B60-B963-807D16D071B1Q31021097-047B59C5-F33D-4253-A41F-31F61ADBC659Q31153194-907114DC-910A-4BD4-B79D-FCB5F710213BQ33881234-22406513-F84C-4E82-ACE1-0B6FBCB67E69Q34364057-F265BE1B-989B-4DEE-B1C7-8C6D43F448D7Q37328714-B1031CA4-51AE-4AD3-AFAF-8CFE07EF76DAQ37538469-7BAA9CFE-2B31-420F-9742-C2C3580958A9Q37836093-1B272DAD-6539-419E-8954-E0829E51F1BAQ38076350-85F56ABD-9ABD-4355-A589-5E16AB38DF0DQ38138249-26938506-CF41-48C5-9983-1DD014E536AFQ38406712-BCCBE34A-FB06-4D40-99F1-59EF146C9CEDQ38657993-DF063CE0-BE07-47E6-B51D-E623D2C49ADDQ38715137-E86ABF47-01C9-4730-AF04-8B85CA109BE7Q38745066-26B9651A-0B46-4E10-96A6-0986D82812D8Q38988087-A16BD5F9-4F3D-4A06-B7F0-4A134C423F2EQ39341401-8F9A663E-180C-41AE-B2F7-B873E17F4FD4Q40179378-A88359AF-A8B0-4736-9094-9A88C7A9D8EDQ40556448-995748BD-6C78-4FB6-B54F-A5D914B22691Q40569388-AC9AD148-6065-4CAD-A9E8-3C23F34F02F6Q41450339-0FF12900-1CB4-45E6-8EF8-A68366F6B56AQ42689661-6DA76AA9-385E-4A59-BD2D-72B33CA8AEEFQ44337775-65E6820A-0FE6-4F44-8F5C-DE17624D7425Q44929998-1C6BEF56-DD8B-4FCD-A088-007887B011D7Q46479144-EF08AE0F-0FE4-48B5-B766-53160E84DEF5Q46531899-4B354A4D-0AC0-423B-825C-ED32D31372B4Q47384645-F978EB74-B0FE-4966-B32F-8DF6CAC304F4Q47693399-7B7FD8B3-E306-4F35-8633-C8122206A4E9Q47781956-5E579DB3-F840-48A9-82D7-081DCBD68276Q48112019-E20A95FF-468A-4783-B3AD-09D15B5B1EFFQ50118813-5D5746D5-66AE-484C-9AE1-CB5566DAF364Q50941629-920541A3-1832-4815-B69A-1F5098599B45Q51741859-F45E497D-12B6-43CE-B4BD-91DD654B416EQ51826669-89DAFBDC-EB27-49F5-8DD5-82CAF58F7DE1Q53393095-FE6BA23D-3E52-4DE0-8B9E-E85E41DF2214Q54998113-B075D31B-A8F0-475D-9AEB-80463D3C9798Q58418512-34C69E3B-7D9B-4B4A-B881-8BD47A6A094CQ58735831-50EBED85-189A-47D9-97C5-657ABE6CEECFQ60241022-7DAAF988-8DE3-42E0-BD62-09D3CE8A4D78Q60300744-94A322AC-F922-4C99-AB5F-6A1D06C5EFE0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ennio Giulio Favalli
@ast
Ennio Giulio Favalli
@en
Ennio Giulio Favalli
@es
Ennio Giulio Favalli
@nl
Ennio Giulio Favalli
@sl
type
label
Ennio Giulio Favalli
@ast
Ennio Giulio Favalli
@en
Ennio Giulio Favalli
@es
Ennio Giulio Favalli
@nl
Ennio Giulio Favalli
@sl
prefLabel
Ennio Giulio Favalli
@ast
Ennio Giulio Favalli
@en
Ennio Giulio Favalli
@es
Ennio Giulio Favalli
@nl
Ennio Giulio Favalli
@sl
P106
P108
P1153
6602431714
P21
P31
P496
0000-0003-1471-6467